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Abstract
Objective
To evaluate the long-term effects of rituximab (RTX) on total and specific immunoglobulins
(Igs) in patients with neuromyelitis optica spectrum disorders (NMOSDs).
Methods
Total IgG, IgA, and IgM levels were evaluated in 15 patients with NMOSDs treated with RTX
(median follow-up 70 months). Anti-aquaporin 4 (AQP4)-IgG titration was performed on
samples from 9 positive patients. Anti-tetanus (TET), anti-varicella-zoster virus (VZV), and
anti-Epstein–Barr virus nuclear antigen (EBNA) IgGs were also tested in patients with
NMOSDs and in 6 healthy controls (HCs).
Results
RTX reduced total IgG by 0.42 g/L per year, IgA by 0.08 g/L per year, and IgM by 0.07 g/L per
year. Hypogammaglobulinemia (hypo-IgG) (IgG < 7 g/L) developed in 11/15 patients. Severe
hypo-IgG (IgG < 4 g/L) was found in 3/15 patients, of whom 2 patients developed serious
infectious complications. In group analysis, anti-AQP4 IgG titers were reduced by RTX over
time, and a significant correlation between anti-AQP4 IgG titers and total IgG levels was found.
The effects of RTX were observed on pathogen-specific IgGs as well. In particular, the levels of
anti-TET IgG in patients were significantly lower than those in HCs. The half-life of anti-TET
IgG was reduced by about 50% in patients compared with the general population.
Conclusions
Long-term RTX treatment is associated with the risk of hypo-Ig and reduction of anti-TET
protection in patients with NMOSDs. Results obtained in this study suggest the importance of
monitoring total and specific Ig levels before and during treatment with anti-CD20 drugs to
prevent hypo-Ig–related complications and to optimize clinical management.
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Rituximab (RTX) is a monoclonal antibody that recognizes
the CD20 antigen expressed on B lymphocytes. Its mecha-
nism of action involves B-cell cytotoxicity through various
pathways.1,2 After more than 2 decades of use, RTX is widely
prescribed not just in the treatment of non-Hodgkin lym-
phomas,3 in which it was first approved, but for a variety of
autoimmune diseases wherein depletion of circulating CD20+
B cells is the common therapeutic goal.4–9 It is also an ef-
fective, yet off-label treatment for neuromyelitis optica spec-
trum disorders (NMOSDs),10,11 a group of inflammatory
immune-mediated demyelinating disorders of the CNS.12,13
Ample evidence exists for major side effects including hypo-
gammaglobulinemia (hypo-Ig) after a prolonged treatment
with RTX in patients with rheumatologic14–16 diseases (table
e-1, links.lww.com/NXI/A70). However, in NMOSDs, the
evaluation of hypo-Ig as a side effect of RTX treatment has
seldom been the focus of the available studies till date (table
e-2, links.lww.com/NXI/A71). A recent study focused on
infectious complications associated with hypo-Ig in 5
patients with NMOSDs treated with RTX.17 In view of the
treatment duration of RTX along with new anti-CD20
therapies with extensive neurologic use (e.g. in MS),18 it is
vital for the clinicians to recognize and manage the safety
concerns and side effects of this drug. Thus, we sought to
characterize the qualitative and quantitative changes in
humoral immunity in patients with NMOSDs during a sus-
tained RTX therapy through the evaluation of total IgG,
IgA, and IgM levels, anti-aquaporin 4 (anti-AQP4) IgG
levels, and of levels of 3 pathogen-specific antibodies. Key
strengths of our study are a long follow-up period, sys-
tematic measurements, and a relatively large number of
patients under study.
Methods
Patients and healthy controls
This is an observational retrospective case series study, in
which serum levels of total IgG, IgA, IgM, and specific IgGs
namely anti-tetanus (TET), varicella-zoster virus (VZV), and
Epstein–Barr virus nuclear antigen (EBNA) were evaluated in
15 patients with NMOSDs undergoing long-term RTX
treatment. This specific humoral immunity was evaluated in 6
healthy controls (HCs) as well.
Patients were followed up at the Regional Reference Centre
for Multiple Sclerosis (CReSM) at Orbassano (Turin, Italy).
The demographic and clinical19–22 details of the patients have
been described in table 1.
All patients were treated with RTX and monitored monthly
according to a treatment-to-target approach, where RTX
reinfusions were given whenever the percentage of
CD19+B cells was more than 0.1% in peripheral blood
mononuclear cells. The details of RTX therapy and of other
treatments given to patients before or during RTX treatment
have been described in table 1. Treatment regimens during
clinical relapses included IV methylprednisolone (1000 mg
for 5 consecutive days without tapering) and/or plasma
exchange courses (PLEX) performed in 3–7 plasmapheresis
procedures every other day for each course or intravenous
immunoglobulin (IVIG) infusions (0.4 g/kg for 5 consec-
utive days for each course).
Themedian follow-up period of RTX treatment in the present
study was 70 (range 17–124) months for a total of 972
person-months of RTX follow-up. Seven patients were fol-
lowed up for at least 70 months. Ninety-one total RTX
infusions were administered (median 4 infusions/patient;
range: 2–13 infusions/patient). The median interval between
treatments was 11 (range: 3–36) months.
Samples selection
A blood sample was collected approximately every 6 (median
6.6; range 5.0–16.5) weeks, following rigorous procedures from
blood collection to serum sample storage. A total of 715 serum
samples were available, stored at −80°C in the CReSM col-
lection. Of note, 236 samples were tested in the present study.
The following selection criteria for samples were applied: (1)
overlap of sample collection time with anti-AQP4 IgG titra-
tion when possible; and (2) exclusion of samples collected
within 3 months since a PLEX or IVIG course or within 1
month after any immunosuppressive treatment withdrawal
(table 1).
Standard protocol approvals, registrations,
and patient consents
All patients provided written informed consent for the use of
their collected samples (approval number 12819/2016).
Laboratory assessments
We performed serologic examinations on 236 samples from
15 patients with NMOSDs. We evaluated total IgG, IgA, and
IgM levels in 188/236 samples (median sampling time in-
terval = 4.9 months, range 3.3–6.2 months). For 84/188
samples (from 7 patients), data on anti-AQP4 IgG titers were
available as well.23 In addition, in the present study, 37 sam-
ples were evaluated for anti-AQP4 IgG titer (median sampling
Glossary
anti-AQP4 = anti-aquaporin 4; EBNA = Epstein–Barr virus nuclear antigen; HC = healthy control; hypo-Ig =
hypogammaglobulinemia; IFI = immunofluorescence; IVIG = IV immunoglobulin; LMM = linear mixed model;
NMOSD = neuromyelitis optica spectrum disorder; PLEX = plasma exchange course; RTX = rituximab; TET = tetanus;
VZV = varicella-zoster virus.
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time interval = 4.5 months, range 3.0–7.0 months). In the
remaining 48/236 samples (median sampling time interval =
13.5 months, range 7–25 months), anti-TET, anti-VZV, and
anti-EBNA IgGs were tested. All the pathogen-specific anti-
gens were tested in 12 samples from 6 HCs as well.
Total immunoglobulin levels
Serum concentrations of IgG, IgM, and IgA were determined
in the Laboratory of Humanitas Hospital Gradenigo (Turin,
Italy) by turbidimetry (DXC 600, Beckman-Coulter)
according to the manufacturer’s instructions. The details re-
garding the detection of Ig levels are shown in table e-3, links.
lww.com/NXI/A72.24,25
Anti-AQP4 IgG titration
According to the latest diagnostic guidelines,13,26 anti-AQP4
IgG titers were assessed and titrated using a commercial in-
direct immunofluorescence (IFI) cell-based assay (FA 1128-
1010-50, Euroimmun, Lubeck, Germany), following the
manufacturer’s instructions.
We used the same procedure as the one used in our previous
studies.23,27
IFI reactions were analyzed using Nikon Eclipse 90i (Nikon)
with a ×20 magnification. Two different operators (F.M. and
P.V.), blinded to the sample type, independently evaluated all
reactions. Euroimmun kindly provided all the kits.
Anti-pathogen specific IgG detection
Anti-TET, anti-VZV, and anti-EBNA IgGs were analyzed in
the CDC Laboratory (Turin, Italy), by commercial ELISA
(SkyLAB™ 752, AXA Diagnostics, Pomezia RM, Italy; Mago
4; Erba, Mannheim, Germany) as per the manufacturer’s
instructions. The details regarding their quantification are
shown in table e-3, links.lww.com/NXI/A72.
Statistical analysis
Differences of continuous variables between groups were
assessed by the unpaired t-test or the Kruskall–Wallis test, as
appropriate, whereas differences of categorical variables by the
Table 1 Demographic and clinical characteristics of patients
Patient ID Sex
Age
at T0a
Follow-
up mo
Serum
samples Disease
Auto-Ab
status
RTX
coursesb
Follow-
up ARR
Other intercurrent
treatmentsc (mo)
or [courses]
Previous treatments
(mo) or [courses]
1 F 38 120 22 NMOd AQP4+ 13 0.3 PLEX [1]
2 F 20 124 21 RLETMd AQP4+ 9 0.1 R-IVIG [3] IFN (14)
3 F 60 70 17 rLETMd AQP4+ 6 0 PLEX [1]
4 F 48 48 13 NMOd AQP4+ 4 1 CFX (3), PLEX [3] MTX (36), AZA (19)
5 M 60 39 8 NMOd AQP4+ 4 0 PLEX [1], PRED (11),
MMF (60)
6 F 57 83 16 NMOd AQP4+ 8 0 MTX (13), IFN (6),
PLEX [1], GA (3)
7 F 25 123 20 NMOd AQP4+ 10 0.2 PLEX [1], R-IVIG [1] IVIG [1]
8 F 21 106 20 rLETMd AQP4− 10 0.8 IVIG [1] PLEX [1]
9 F 50 106 20 rLETMd AQP4− 10 0.2
10 F 57 23 6 rON AQP4− 3 0 PLEX [1]
11 F 77 24 6 NMOd AQP4+ 4 0 PLEX [1], AZA (1),
MMF (4)
12 F 59 20 5 rONd MOG+ 2 1.2
13 M 23 23 7 LETM AQP4− 4 0
14 F 36 10 2 NMOd AQP4+ 2 0 PLEX [1]
15 F 43 17 5 rLETMd AQP4− 2 2.1 IVIG[1] MTX (12)
Abbreviations: ARR = annualized relapse rate; AZA = azathioprine; CFX = cyclophosphamide; GA = glatiramer acetate; IFN = interferonβ-1a; IVIG = intravenous
immunoglobulin; MMF =mycophenolatemofetil; MTX =mitoxantrone; NMO = neuromyelitis optica; NMOSD = neuromyelitis optica spectrum disorder; PLEX
= plasma exchange; PRED = oral prednisolone (5 mg every other day); rLETM = (recurrent) longitudinally extensive transverse myelitis; R-IVIG = intravenous
immunoglobulin replacement therapy; rON = recurrent optic neuritis; RTX = rituximab.
Patients not completely matching the 2015 criteria for NMOSD diagnosis (their treatment regimen was the same, given the presence of acute neurologic
episodes, suggesting an autoimmune inflammatory disorder at risk of developing relapses and converting to NMOSD19–22).
a T0: beginning of RTX treatment.
b Initial RTX dose: 375 mg/m2 once a week for 4 weeks; subsequent RTX courses: 1000 mg infused twice, with a two-week interval.
c Only treatments interfering with Ig levels were considered.
d Diagnosis according to 2015 Wingerchuck revised diagnostic criteria.13
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Fisher exact test. Correlation between continuous variables
was assessed by means of the Pearson correlation. Correla-
tion between IgG levels and anti-AQP4 IgG titers was
evaluated by a linear regression model. Univariate linear
mixed models (LMMs) with time as a fixed effect and
patients as random intercepts were performed to investigate
the longitudinal effect of RTX treatment on the Ig titer. An
LMM with time and group (patient/control) as fixed effects
and participants as random intercepts was used to examine
the longitudinal changes of anti-TET IgG and to compare
them between patients and controls. The anti-TET IgG half-
life (T1/2) of patients was calculated from the coefficient of
the fixed effect of time in an LMM run with patients’ data
only. Anti-TET IgG concentrations were log-transformed to
make data conform to normality. p values were obtained by
likelihood ratio tests of the full models against the models
without the effect of interest. All analyses were run with R
software (r-project.org).
Data availability
Individual de-identified patient data not published within the
article including clinical evaluations, IgG, IgA, and IgM levels,
anti-AQP4 IgG titers, and specific anti-pathogen IgG levels
will be shared upon request from any qualified investigator.
Results
Hypo-Ig as an effect of RTX treatment
Reduction of IgG, IgA, and IgM levels during RTX
treatment
In the present study, the longitudinal effect of RTX treatment
on total Ig levels was investigated using univariate LMMs
(figure 1).
RTX significantly reduced total IgG by 0.42 g/L per year
(LMM, p < 0.0001, 95% CI, −0.49 to −0.35), IgA by 0.08 g/L
(LMM, p < 0.0001, 95% CI, −0.09 to −0.06), and IgM by
0.07 g/L (LMM, p < 0.0001, 95% CI, −0.09 to −0.06).
Hypogammaglobulinemia
In the present study, hypo-IgG (IgG < 7.0 g/L) was found in
11/15 (73%) patients in at least 1 measurement. Notably, in
4/11 patients, hypo-IgG status was present before the start of
RTX treatment. Of note, 3/15 (20%) patients demonstrated
severe hypo-IgG (IgG <4.0 g/L) in at least 1 measurement
(figure e-1, links.lww.com/NXI/A66).
Hypo-IgA (IgA < 0.7 g/L) was found in 6/15 (40%) patients.
In 2 patients, this deficiency was present before the start of
RTX treatment (figure e-2, links.lww.com/NXI/A67).
Hypo-IgM (IgM < 0.4 g/L) was found in 9/15 (60%)
patients. In 1 patient, this deficiency was present before the
start of RTX treatment. Of note, 2/15 (13%) patients de-
veloped severe hypo-IgM (IgM < 0.2 g/L) in at least 1
measurement (figure e-3, links.lww.com/NXI/A68).
The prevalence of hypo-IgG, hypo-IgA, and hypo-IgM, eval-
uated in patients with a prolonged follow-up period (≥5 years,
n = 7 patients), increased over time during RTX treatment
(figure 1, B, D, F).
Correlation between Ig classes
A strong correlation was found between the IgG class and IgA
or IgM concentrations (Pearson correlation; p < 0.0001; r =
0.51 and r = 0.49, respectively), whereas IgA and IgM serum
concentrations were weakly correlated (Pearson correlation;
p < 0.0001; r = 0.34) (figure e-4, links.lww.com/NXI/A69).
Moreover, the occurrence of hypo-IgG was significantly as-
sociated with the occurrence of hypo-IgA, IgM, or both
(Fisher exact test, p = 0.002).
Infectious complications
Two patients (#2 and # 8) developed infectious complications
after 9 and 8 years of RTX treatment (8 and 5 RTX infusions),
respectively. Total IgG concentration during that period was
3.6 g/L and 3.5 g/L, respectively. In addition, IgM serum
concentration of patient 2 decreased to 0.14 g/L during the
same period. Such low levels are considered as risk factors for
bacterial infections.24,25 Patient 2 developed pneumonia along
with hand, foot, and mouth disease. Consequently, a new
treatment regimen, including RTX and monthly IVIG re-
placement treatment, was required. On the other hand, patient
8 developed multifocal bilateral pyelonephritis, which was
treated with wide-spectrum antibiotics. In this case, severe
hypo-IgGwas present, although not investigated. In fact, in that
period, there were scant evidences of RTX-induced hypo-Ig.
IgG levels and anti-AQP4 IgG titer
In group analysis, anti-AQP4 IgG serum levels showed a sig-
nificant reduction in annualmedian titer (Kruskal–Wallis test, p
< 0.0001) (figure 2A). In individual analysis, reduction in anti-
AQP4 IgG titers was not observed in patients 4 and 5, whereas
patient 2 became negative for anti-AQP4 IgG during the RTX
follow-up period. On exclusion of patients 4 and 5, a strong
correlation was found between total IgG levels and anti-AQP4
IgG titers (linear regression model; p < 0.0001) (figure 2B).
Effect of RTX on specific humoral immunity
Longitudinal effects of RTX on specific humoral immunity
were evaluated on 3 pathogen-specific IgGs.
Anti-TET IgG
Anti-TET IgG levels were found to be below the protection
threshold (≤0.1 IU/mL) at the beginning of the follow-up in
4/15 (27%) patients. In 1/15 (7%) patients, the concentra-
tion of anti-TET IgG decreased below the defined threshold
during RTX treatment. By contrast, anti-TET IgG levels were
never found to be below the protection threshold in HCs.
Anti-TET IgG showed a reduction in 10/15 patients and in 3/
6 HCs (figure 3A).
Further analyses were conducted on anti-TET IgG, based on
the quantitative nature of the measurements. The analyses
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were performed after excluding values which showed a dou-
bling of the previous level, thus identifying an anti-TET vac-
cination recall.28
Here, the levels of anti-TET IgG during RTX treatment were
found to be significantly lower as compared to HCs (unpaired
t test, p = 0.006) (figure 3B).
Figure 1 Total IgG, IgA, and IgM levels and hypo-Ig prevalence during RTX treatment
IgG, IgA, and IgM levels were measured in 188 samples from 15 patients with NMOSDs treated with RTX. Median follow-up period was 70 (range 17–124)
months. Levels of total IgG, IgA, and IgM in all serum samples are represented in panels A, C, and E, respectively. Black lines represent the thresholds defining
hypo-IgG (<7.0 g/L), –IgA (<0.7 g/L), and –IgM (<0.4 g/L). In addition, based on augmented infectious risk, severe hypo-IgGwas defined as total IgG levels <4.0 g/
L and severe hypo-IgM as total IgM levels <0.2 g/L. Long-term RTX treatment reduced the levels of all Ig classes. Statistical analysis was performed using
univariate linear mixed models. Panels B, D, and F show the prevalence of hypo-Ig over time according to each specific cutoff. The percentage of patients
developing hypo-IgG, hypo-IgA, and hypo-IgM has been calculated in patients with a prolonged follow-up period (≥5 years, n = 7 patients), which showed an
increased prevalence over time. In particular, prevalence of patients developing hypo-IgG is represented in panel B: patients developing severe hypo-IgG (IgG
< 4g/L) are represented in purple, as patients showingmild hypo-IgG (5 g/L ≤ IgG < 7 g/L) are represented in gray. Prevalence of patients developing hypo-IgA
(IgA < 0.7 g/L) is shown in panel D (gray). Prevalence of patients developing hypo-IgM is shown in panel F: patients developing severe hypo-IgM (IgM <0.2 g/L)
are represented in purple, as patients showing mild hypo-IgM (0.2 g/L ≤ IgG < 0.4 g/L) are represented in gray.
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In addition, anti-TET IgG T1/2 in seroprotected patients
(anti-TET IgG > 0.1 IU/mL at beginning of the follow-up
period) was 5.52 years (95%CI: 3.63–10.89), which represents
a 50% reduction compared with the general population.28
Anti-VZV and anti-EBNA IgG
Anti-VZV negativity was found in 1 patient since the beginning
ofmonitoring, whereas another patient developed it during RTX
treatment. No individuals from theHC group showed a negative
status. On the other hand, anti-EBNA negativity was found in
both 1 HC and 1 patient since the beginning of monitoring.
Anti-VZV and anti-EBNA IgG showed a reduction in 8/15
patients and 0/6 controls and in 12/15 patients and 1/6
controls, respectively (figure 3, C and D).
LMMs could not be performed for anti-VZV and anti-EBNA
IgG because their levels were expressed as “Index” and not as
quantitative concentrations.
Discussion
There has been a continuous increase in the usage of anti-
CD20 drugs in the treatment of CNS autoimmune diseases
during the past decade. This will be further reinforced by the
therapeutic indications of recently approved ocrelizumab for
MS. There is a significant proportion of patients with MS and
NMOSDs who positively respond to anti-CD20 drugs such as
RTX.11,21 Thus, it is vital to consider the side effects of these
drugs from a wider temporal perspective, given the long-term
treatment regimens used in themanagement of these diseases.
RTX has been used “off label” for more than a decade in
NMOSDs. The present study evaluates the long-term effects
of RTX in patients with NMOSDs on total Ig levels, anti-
AQP4 IgG levels, and on levels of 3 pathogen-specific IgGs
(anti-TET, anti-VZV, and anti-EBNA IgG).
A study published recently in this field has investigated the
secondary antibody deficiency as a complication of long-term
RTX therapy in patients with NMOSDs.17 In comparison, the
key strengths of our study include the largest median follow-up
period among studies on NMOSDs in addition to sample se-
lection based on strict criteria to reduce the effect of confounding
variables. Serum samples used in this study were collected from
patients with NMOSDs and stored in the CReSM Collection,
following rigorous and consistent procedures.
We observed a significant reduction in total IgG, IgA, and IgM
levels in patients with NMOSDs after long-term RTX treat-
ment (figure 1). A strong correlation was observed between
the 3 classes (figure e-4, links.lww.com/NXI/A69). Conse-
quently, these changes might stem from a single phenomenon
of the sustained depletion of CD20 + Ig—secreting circulating
B cells. These B cells are responsible for a significant portion
of immunoglobulin synthesis,29,30 as well as for replenishment
of plasmablasts and plasma cell compartments.31 In our co-
hort, hypo-IgG occurred in 11/15 patients (73%), hypo-IgA
in 6/15 patients (40%), and hypo-IgM in 9/15 patients (60%)
during treatment. The percentage of hypo-Ig patients in-
creased over time (figure 1). Comparable results have been
demonstrated by studies on rheumatic diseases with similar
follow-up and RTX dose characteristics14–16(table e-1, links.
lww.com/NXI/A70).
Although the group analysis demonstrates a reduction of Igs
during RTX treatment, the individual analysis presents dis-
parate Ig concentrations across patients. We then attempted
to identify the presence of any association between Ig levels
and clinical demographic variables. In patients with at least 2
years of follow-up, no differences in age, IgG baseline levels, or
annualized relapse rate were found between patients showing
a reduction of IgG over time and patients showing a stable
level of IgG during follow-up (data not shown).
Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer
Anti-AQP4 IgG levels were measured in 121 samples from 9 patients positive to AQP4 antibodies. Anti-AQP4 IgG titer decreases during the RTX follow-up
period (panel A, Kruskal–Wallis test, p = 0.0001). One of 9 patients (#2) seroreverted during the follow-up period. A strong correlation between total IgG and
anti-AQP4 IgG levels was shown in 7 of 9 patients (panel B; linear regression model, p < 0.0001).
6 Neurology: Neuroimmunology & Neuroinflammation | Volume 5, Number 6 | November 2018 Neurology.org/NN
Notably, all patients demonstrated a depletion of CD19 + B cells
after each RTX infusion, indicating the biological effectiveness
of the drug. No association between the occurrence of hypo- or
severe hypo-Ig and baseline Ig values, the number of RTX
cycles, and the duration of treatment was found. Finally, no
relationship was found between previous immunosuppressive
Figure 3 Effects of RTX on specific anti-pathogen IgGs
Anti-TET, anti-VZV, and anti-EBNA IgGs were tested in 48 samples from 15 patients with NMOSDs and in 12 samples from 6 HCs. Panels A, C, and D show the
over-time variation in the levels of anti-TET IgG, anti-VZV, and anti-EBNA IgG index in patientswith NMOSDs (circle, black line) and in HCs (triangle, purple line).
The first measurement (open circle or triangle) and the last available measurement (closed circle or triangle) among the entire follow-up period were
considered for each subject. Anti-TET IgG showed a reduction in 10/15 patients and in HCs (A). The yellow line shows the threshold of ineffective protection
from tetanus (light-gray zone, anti-TET IgG <0.1 U/mL). The levels of anti-TET IgG resulted significantly lower in patients during RTX treatment as compared to
HCs (B). Anti-VZV IgG was reduced in 8/15 patients and 0/6 controls (C). The yellow line shows the threshold of negativity status for anti-VZV (light-gray zone,
index ≤1.0). Seven patients with NMOSDs and 3 HCs showed levels of anti-VZV IgG index upper the limit of detection (index >6.4, dark-gray zone).
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treatments and basal hypogammaglobulinemia condition (data
not shown). It is important to note that the sample size of our
cohort does not allow for adequate statistics to be performed for
such analyses.
However, the heterogeneity emerging in this case series study
is a motivation to plan further studies on this side effect, given
the evidence in literature wherein, in a variable proportion of
cases, Ig deficit was further complicated by infections16 and
could require an Ig-replacement therapy.32,33
In our cohort, 3/15 patients showed IgG concentrations be-
low 4 g/L during treatment, a level indicative of augmented
infectious risk.24,25 Similarly, another independent risk factor,
i.e. IgM serum concentration <0.2 g/L, was found in 2 of our
patients. Both these conditions are associated with increased
incidence of bacterial infections, especially affecting the air-
way.25 In our cohort, 2 patients (13.3%) developed severe
infectious complications while having hypo-IgG status. Based
on the design and intent of the current study, it is not possible
to make any conclusive statement regarding the causal re-
lationship between serious infections and RTX/hypo-Ig.
However, we do speculate that a relationship might exist
between infections and RTX/hypo-Ig as supported by the
following evidences: (1)We never observed serious infections
in other RTX-treated patients wherein IgG and IgM levels
were normal; (2) serious infections have never been reported
by the same patients during other treatments before starting
RTX; and (3) the prevalence of serious infectious events in
our cohort is in line with those reported in the literature.27
In addition to total Ig (IgG, IgA, and IgM), we investigated
several specific IgGs (i.e. anti-AQP4 IgG and anti-pathogen
IgGs). In patients with NMOSDs, anti-AQP4 IgG titers have
been suggested to be related to biological and clinical re-
sponse to RTX treatment.34,35 Data from this study confirmed
our previous findings regarding the reduction of anti-AQP4
IgG titer during long-termRTX treatment23 in a bigger cohort
of patients (figure 2A). Of interest, in individual analysis, such
a reduction was not observed in 2 patients (#4 and #5). Both
patients showed high anti-AQP4 IgG titers during their entire
follow-up period. In particular, patient 4 was considered
a clinical nonresponder to RTX and was shifted to tocilizumab
after 4 years of treatment and 4 RTX infusions. A correlation
was observed between IgG levels and anti-AQP4 IgG titers on
excluding these patients with anomalous titers (figure 2B).
The systematic evaluation of the levels of specific anti-
pathogen IgGs during RTX therapy is rare in the literature.
Yet, this aspect is of particular interest, given the long-term
management of patients with NMOSDs and/or for patients
treated with anti-CD20 drugs. The effects of RTX on anti-
TET IgG were investigated because of previous evidences of
specific protection and immunization impairments in RTX-
treated patients and the importance of short half-life sero-
protection during such a long-term therapy. Anti-VZV and
anti-EBNA IgGs levels were also measured to gain novel
insights about temporal changes of specific humoral immunity
against latent viral pathogens during B-cell depletion.
A reduction in the analyzed anti-pathogen IgG levels was
observed more frequently in RTX-treated patients compared
with HCs (figure 3). Also, our results highlight anti-TET IgG
half-life of 5.52 years (95% CI: 3.63–10.89), representing
a substantial (50%) reduction as compared to the estimated
T1/2 in the general population.28 These patients, therefore,
might be at a risk to become unprotected from tetanus un-
expectedly and may require additional vaccination. This is of
particular interest, given an immunosuppressive therapy,
which has been proven to impair the efficacy of active im-
munization with either recall or new, bacterial or viral
antigens.36
Given these results, it is important to mention the limitations
of the current study. First, this is a retrospective study on
a small group of patients. The analysis of specific anti-
pathogen IgGs was restricted to only 3 pathogens. Moreover,
it was conducted specifically only on RTX treatment with
a “treatment-to-target” approach. RTX maintenance regimen
with fixed reinfusion intervals (mainly every 6 months)18
could further enhance hypo-Ig risk in comparison with the
regimen used in this study (resulting in 11-month reinfusion
rate). In fact, data from ocrelizumab phase III trials showed
a 16% hypo-IgM incidence after the first year of treatment.37
Our data demonstrate a 7% incidence at a similar time point.
In spite of these limitations, the present study is based on
a high number of measurements, a long follow-up period, and
a rigorous selection of samples. Thus, an attempt may be
made to provide practical suggestions for neurologists in-
volved in the management of patients with NMOSDs andMS
treated with both existing and novel anti-CD20 drugs
(table 2).
The concentration of serum Ig should be measured before
therapy and at least once a year during treatment. In the
present study, we did not observe any sudden reductions in Ig
levels throughout the treatment course. Based on our data,
annual monitoring provides information regarding the change
in Ig concentration over time. Such monitoring could prevent
persistent Ig deficiency and would be useful for the prevention
of infectious complications as well. Of importance, any de-
crease in IgG levels below the warning threshold (4 g/L) was
always preceded by deficient (hypo-IgG) values for more than
a year during our study.
Regarding anti-pathogen IgGs, our data strongly suggest
measurement of anti-TET IgG before starting RTX and to
perform vaccination if necessary. Moreover, anti-TET IgG
should be measured at least after 5 years to evaluate any
further need to ensure seroprotection (table 2).
Finally, this study highlights the phenomenon of long-term
RTX treatment inducing a reduction in specific anti-pathogen
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IgGs. Humoral defense against hepatitis B virus and anti-
pneumococcal polysaccharide IgG have been found to be
reduced38 after RTX treatment, suggesting the need for vig-
ilant monitoring of anti-pathogen IgGs. The reduction in
specific anti-pathogen IgGs could be of vital importance when
patients with MS treated with RTX or other anti-CD20 drugs
are being considered for a shift to fingolimod or natalizumab
who require a serologic screening for anti-VZV and anti-JC
virus IgG, respectively.39
To recapitulate, the present study demonstrates that long-
term RTX treatment is associated with the risk of hypo-Ig
and reduction in anti-TET protection in patients with
NMOSDs. Monitoring total and specific Ig levels before
and during treatment with RTX might prevent hypo-Ig–
related complications. Further studies involving a larger
number of participants are needed to evaluate similar
effects of other anti-CD20 drugs used to treat CNS auto-
immune disorders to optimize the clinical management of
patients.
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Table 2 Clinical suggestions for management of patients
undergoing anti-CD20 treatment
Clinical suggestions
Ig serum concentrations
Evaluate IgG, IgA, and IgM levels before start of RTX treatment.
Repeat measurements yearly.
Focus monitoring on patients who show
Hypo-IgG and/or hypo-IgM (particularly if at baseline).
Accelerated IgG decay.
Anti-TET IgG
Check for presence of anti-TET serum protection before start of RTX
treatment.
Repeat vaccination in unprotected cases.
Consider revaccination in low-level protected patients (<1.0 IU/mL)
because of accelerated anti-TET IgG decay.
Repeat measurement within 5 years.
Future perspectives
Other specific anti-pathogen IgGs in RTX-treated patients
HBsAb levels: Risk of reactivation of latent HBV infection in RTX-treated
patients38
Anti-PP IgG: Long-term changes in seroprotection and immunization
impairment36
Other specific anti–pathogen IgGs in patients with MS
Possible “false negativity” for anti-JCV IgG after RTX treatment.
Possible “false negativity” for anti-VZV IgG after RTX treatment.
Abbreviations: anti-PP = anti-pneumococcal polysaccharide; anti-TET = anti-
tetanus; anti-VZV = varicella-zoster virus; HBsAB = hepatitis B surface
antibody; HBV = hepatitis B virus; hypo-Ig = hypogammaglobulinemia; Ig =
immunoglobulin; RTX = rituximab.
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